Журнал кардиореспираторных исследований 2026. №3

Subject of the article

Bronxial astma va 2-tip qandli diabet bilan kasallangan bemorlarda sitokin va metabolik yallig‘lanishning o‘zaro bog‘liqligi (98-101)

Authors

Ubaydullayeva N.N., Xaydarova F.A., Ismatullayeva S.S.

Institution

Tibbiyot xodimlarining kasbiy malakasini rivojlantirish markazi, Akademik Yo.X. To‘raqulov nomidagi Respublika ixtisoslashtirilgan ilmiy-amaliy tibbiyot endokrinologiya markazi

Abstract

Maqolada bronxial astma (BA) va 2-tip qandli diabet (QD2) bilan og‘rigan bemorlarda uglevodlar almashinuvi buzilishlari va sitokin profili o‘rtasidagi o‘zaro bog‘liqlik, shuningdek, metformin qo‘llanilishiga qarab BA nazoratining xususiyatlari o‘rganilgan. Jami 90 nafar bemor tekshirildi: BA+QD2, izolyatsiyalangan BA va izolyatsiyalangan QD2 bo‘lgan guruhlarning har biriga 30 nafardan bemor kiritildi. BA va QD2ning birgalikda kechishi uglevodlar almashinuvining yanada yaqqol buzilishi va proyallig‘lanish faolligining oshishi bilan tavsiflanishi aniqlandi. BA+QD2 bo‘lgan bemorlarda IL-6 darajasi izolyatsiyalangan BA bilan og‘rigan bemorlarga nisbatan yuqori bo‘ldi (37,8±25,7 ga nisbatan 19,9±23,0 pg/ml; p=0,02), och qoringa glikemiya ≥10,5 mmol/l bo‘lganda esa uning konsentratsiyasi kamroq ifodalangan giperglikemiyaga nisbatan sezilarli darajada yuqori bo‘ldi. Metformin qabul qilgan bemorlarda BA nazorati ACT bo‘yicha yuqoriroq ekanligi aniqlandi (16,5±2,1 ga nisbatan 12,1±2,8 ball; p<0,05), biroq kasallik qo‘zishi chastotasi bo‘yicha statistik jihatdan ahamiyatli farqlar aniqlanmadi. Olingan natijalar BA va QD2ning birgalikda kechishida metabolik buzilishlar hamda proyallig‘lanish sitokin faolligi o‘rtasida o‘zaro bog‘liqlik mavjudligini ko‘rsatadi, metformin qo‘llanilishi esa bronxial astmaning yaxshiroq nazorati bilan assotsiatsiyalanadi.

Key words

bronxial astma, 2-tip qandli diabet, IL-6, IL-10, giperglikemiya, insulinorezistentlik, HOMA-IR, metformin, ACT.

Literature

1. Pham A., Corcoran R., Foer D. The role of type 2 diabetes in the severity of adult asthma // Current Opinion in Allergy and Clinical Immunology. 2025. Vol. 25, No. 1. P. 34–40. DOI: 10.1097/ACI.0000000000001045. 2. Peters M.C., Schiebler M.L., Cardet J.C. et al. The Impact of Insulin Resistance on Loss of Lung Function and Response to Treatment in Asthma // American Journal of Respiratory and Critical Care Medicine. 2022. Vol. 206, No. 9. P. 1096–1106. DOI: 10.1164/rccm.202112-2745OC. 3. Yang G., Han Y.Y., Forno E. et al. Glycated Hemoglobin A1c, Lung Function, and Hospitalizations Among Adults with Asthma // Journal of Allergy and Clinical Immunology: In Practice. 2020. Vol. 8, No. 10. P. 3409–3415.e1. DOI: 10.1016/j.jaip.2020.06.017. 4. Peters M.C., Mauger D., Ross K.R. et al. Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency // American Journal of Respiratory and Critical Care Medicine. 2020. Vol. 202, No. 7. P. 973–982. DOI: 10.1164/rccm.201909-1813OC. 5. Wu T.D., Fawzy A., Akenroye A. et al. Metformin Use and Risk of Asthma Exacerbation Among Asthma Patients with Glycemic Dysfunction // Journal of Allergy and Clinical Immunology: In Practice. 2021. Vol. 9, No. 11. P. 4014–4020.e4. DOI: 10.1016/j.jaip.2021.07.007.